Rosuvastatin in Visceral Adiposity

• Status: Completed
• Trial end date: 2008-12-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to investigate whether 6 months treatment with the cholesterol-lowering drug rosuvastatin may reduce visceral fat tissue in obese middle aged men.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Göteborg University
• Collaborator: Sahlgrenska University Hospital, Sweden
• Treatments: Rosuvastatin Calcium

Criteria

Inclusion Criteria:

• Male patients between 40 and 65 years of age.

• Abdominal obesity

• Dyslipidemia

• Written informed consent.

Exclusion Criteria:

• Uncontrolled hypertension

• Diabetes mellitus

• Severe liver disease

• Severely reduced renal function

• Uncontrolled endocrine disorders

• History of or ongoing malignant disease

• Patients with known myopathic disease

• Recent alcohol or drug abuse

• Weight loss or weight gain during the three months prior to screening.

• Ongoing treatment with statins

• Ongoing treatment with calcineurin-inhibitors

• Ongoing treatment with anti-inflammatory drugs

• Received an investigational drug within 30 days prior to screening.

• Strong clinical indication for statin treatment

• In the Principal Investigator's opinion, the patient has other clinically significant cardiac, oncologic, neurologic or psychiatric disease that could be adversely affected by Study participation.

• For any reason the patient is considered by the Principal Investigator to be an unsuitable candidate to participate in the Study.